Literature DB >> 31926868

The impact of pharmacist care on diabetes outcomes in primary care settings: An umbrella review of published systematic reviews.

Sara Abdulrhim1, Sowndramalingam Sankaralingam1, Mohamed Izham Mohamed Ibrahim1, Ahmed Awaisu2.   

Abstract

OBJECTIVE: To systematically review published systematic reviews (SRs) examining the impact of pharmacist interventions in multidisciplinary diabetes care teams on diabetes-related clinical, humanistic, and economic outcomes in primary care settings.
METHODS: PubMed, EMBASE, Scopus, Database of Abstracts of Reviews of Effects, Cochrane Library, Joanna Briggs Institute (JBI) Database, Google Scholar, and PROSPERO were searched from inception to 2018. Studies published in English evaluating the effect of pharmacist interventions on diabetes outcomes were included. Two independent reviewers were involved in screening of titles and abstracts, selection of studies, and methodological quality assessment.
RESULTS: Seven SRs were included in the study. Three of them included only randomized controlled trials, while the rest involved other study designs. Educational interventions by clinical pharmacists within the healthcare team were the most common types of interventions reported across all SRs. Pharmacist's interventions compared to usual care resulted in favorable significant improvements in hemoglobin A1c (HbA1c), fasting blood glucose, blood pressure, body mass index, total cholesterol, low density lipoprotein, high density lipoprotein and triglycerides in more than 50% of the SRs. Improvement in HbA1c was the mostly reported clinical outcome of pharmacist intervention in the literature (reported in six SRs). Pharmacist's interventions led to significant cost-saving ($8-$85,000 per person per year), cost-utility, and cost-benefit (benefit-to-cost ratio range from 1:1 to 8.5:1) versus usual care. Pharmacist's interventions improved patients' quality of life (QoL) in three SRs; however, no conclusion can be drawn due to the use of diverse QoL assessment tools.
CONCLUSIONS: Most SRs support the benefit of pharmacist care on diabetes-related clinical, humanistic, and economic outcomes in primary care settings. Improvements in diabetes outcomes can significantly reduce the burden of diabetes on healthcare system. Hence, the incorporation of pharmacists into multidisciplinary diabetes care teams is beneficial and should be strongly considered by clinicians and health policymakers.
Copyright © 2019 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clinical outcomes; Collaborative care; Diabetes; Economic outcomes; Humanistic outcomes; Pharmacist care; Primary care

Year:  2020        PMID: 31926868     DOI: 10.1016/j.pcd.2019.12.007

Source DB:  PubMed          Journal:  Prim Care Diabetes        ISSN: 1878-0210            Impact factor:   2.459


  6 in total

1.  Impact of pharmacist-involved collaborative care on diabetes management in a primary healthcare setting using real-world data.

Authors:  Sara Abdulrhim; Ahmed Awaisu; Mohamed Izham Mohamed Ibrahim; Mohammad Issam Diab; Mohamed Abdelazim Mohamed Hussain; Hend Al Raey; Mohammed Thahir Ismail; Sowndramalingam Sankaralingam
Journal:  Int J Clin Pharm       Date:  2021-10-12

2.  The Evolution of Drug Information Services to Asynchronous Delivery of Pharmacist eConsults.

Authors:  Valerie Clinard; Marilyn Stebbins; Shalini Lynch
Journal:  J Pharm Technol       Date:  2021-10-01

3.  Intervention by clinical pharmacists can improve blood glucose fluctuation in patients with diabetes and acute myocardial infarction: A propensity score-matched analysis.

Authors:  Fang-Hong Shi; Long Shen; Jiang Yue; Jing Ma; Zhi-Chun Gu; Hao Li; Hou-Wen Lin
Journal:  Pharmacol Res Perspect       Date:  2021-04

4.  Rationale and Design of a Pharmacist-led Intervention for the Risk-Based Prevention of Heart Failure: The FIT-HF Pilot Study.

Authors:  Michael C Wang; Bridget Dolan; Benjamin H Freed; Lourdes Vega; Nikola Markoski; Amy E Wainright; Bonnie Kane; Laura E Seegmiller; Katharine Harrington; Alana A Lewis; Sanjiv J Shah; Clyde W Yancy; Ian J Neeland; Hongyan Ning; Donald M Lloyd-Jones; Sadiya S Khan
Journal:  Front Cardiovasc Med       Date:  2021-11-29

5.  The 2020 CCS atrial fibrillation guidelines for pharmacists: Top 10 takeaways.

Authors:  Kori Leblanc; Jenny MacGillivray; Amanda Carroccia; Laurent Macle; Jason G Andrade
Journal:  Can Pharm J (Ott)       Date:  2021-11-17

6.  Clinical and humanistic impact of pharmacotherapeutic follow-up in patients with type 1 diabetes mellitus treated judicially.

Authors:  Thays S Mendonça; William N Oliveira; Vinícius S Belo; Eduardo S Silva; Mariana L Pereira; Paulo R Obreli-Neto; André O Baldoni
Journal:  Diabetol Metab Syndr       Date:  2022-05-03       Impact factor: 5.395

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.